|
SAVA | Cassava Sciences Inc |
|
|
SAVA | Cassava Sciences Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.72 |
| Leverage | 37.13% |
| Market Cap | $ 113.7m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -105.9m |
| Margin | 70115.11% |
Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.